IQVIA Holdings Inc. $IQV Stock Purchased by Vontobel Holding Ltd.

Key Points

• Vontobel Holding increased its IQVIA stake by 12% in the third quarter, acquiring 30,348 additional shares and bringing its holdings to 282,916 shares worth approximately $76.1 million. Institutional investors and hedge funds collectively own 89.62% of IQVIA.
• IQVIA reported quarterly adjusted earnings of $3.15 per share and revenue of $4.37 billion, exceeding analyst expectations, while revenue rose 8.7% year over year. The company issued fiscal 2026 EPS guidance of $12.80 to $13.00.
• Analysts remain broadly bullish, with the stock carrying a consensus “Moderate Buy” rating and an average price target of $276; several firms recently raised their targets to between $303 and $345.

Vontobel Holding Ltd. grew its stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 12.0% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 282,916 shares of the medical research company's stock after buying an additional 30,348 shares during the quarter. Vontobel Holding Ltd. owned about 0.17% of IQVIA worth $76,062,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of the company. Pension & Wealth Management Advisors Inc. acquired a new stake in shares of IQVIA in the third quarter valued at $30,000. Compass Financial Management LLC bought a new position in IQVIA during the second quarter valued at about $27,000. Financial Freedom LLC acquired a new position in IQVIA during the first quarter worth about $25,000. Ascentis Independent Advisors acquired a new position in IQVIA during the first quarter worth about $25,000. Finally, Elevation Wealth Partners LLC grew its holdings in IQVIA by 218.8% during the second quarter. Elevation Wealth Partners LLC now owns 153 shares of the medical research company's stock worth $30,000 after acquiring an additional 105 shares during the period. 89.62% of the stock is currently owned by institutional investors and hedge funds.

IQVIA Trading Down 1.5%

IQV traded down $4.04 during trading on Friday, reaching $267.00. The company had a trading volume of 1,037,035 shares, compared to its average volume of 1,546,768. The firm's 50-day simple moving average is $260.76 and its 200 day simple moving average is $212.85. The company has a debt-to-equity ratio of 2.18, a quick ratio of 0.71 and a current ratio of 0.71. The company has a market cap of $43.95 billion, a price-to-earnings ratio of 33.13, a PEG ratio of 2.35 and a beta of 1.17. IQVIA Holdings Inc. has a 12-month low of $154.50 and a 12-month high of $277.40.

IQVIA (NYSE:IQV - Get Free Report) last announced its quarterly earnings data on Tuesday, July 28th. The medical research company reported $3.15 EPS for the quarter, topping analysts' consensus estimates of $3.03 by $0.12. IQVIA had a return on equity of 30.25% and a net margin of 8.10%. The firm had revenue of $4.37 billion during the quarter, compared to analyst estimates of $4.30 billion. During the same period last year, the company posted $2.81 EPS. The business's quarterly revenue was up 8.7% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. Equities research analysts anticipate that IQVIA Holdings Inc. will post 11.56 earnings per share for the current year.

Insider Transactions at IQVIA

In other IQVIA news, insider James G. Berkshire sold 2,668 shares of the company's stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $261.33, for a total value of $697,228.44. Following the transaction, the insider directly owned 10,890 shares of the company's stock, valued at $2,845,883.70. This represents a 19.68% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Bhavik Patel sold 1,855 shares of the firm's stock in a transaction that occurred on Friday, July 31st. The shares were sold at an average price of $235.27, for a total transaction of $436,425.85. Following the transaction, the insider directly owned 1,348 shares in the company, valued at approximately $317,143.96. The trade was a 57.91% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 15,581 shares of company stock valued at $3,796,021. Corporate insiders own 1.70% of the company's stock.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on IQV. Stifel Nicolaus upped their price target on shares of IQVIA from $276.00 to $303.00 and gave the company a "buy" rating in a report on Wednesday. Truist Financial reiterated a "buy" rating and issued a $329.00 target price (up from $300.00) on shares of IQVIA in a report on Monday, September 28th. UBS Group initiated coverage on shares of IQVIA in a research note on Wednesday, September 30th. They set a "buy" rating and a $345.00 target price for the company. William Blair raised shares of IQVIA to a "strong-buy" rating in a research note on Tuesday, July 28th. Finally, JPMorgan Chase & Co. raised their target price on shares of IQVIA from $225.00 to $285.00 and gave the stock an "overweight" rating in a report on Wednesday, July 29th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $276.00.

IQVIA Profile

IQVIA Holdings Inc NYSE: IQV is a global provider of technology, analytics and contract research services for the life sciences industry. The company helps pharmaceutical, biotechnology and medical device organizations develop products, manage clinical trials, understand healthcare markets and improve commercial performance.

IQVIA's offerings include clinical research and trial management, real-world data and evidence, healthcare analytics, technology platforms, consulting, and commercial services such as sales support and patient engagement.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.